glp1InjectablePrescription only (US)FDA-approved as Adlyxin for type 2 diabetes; marketed as Lyxumia in the EUInvestigational use for Parkinson's disease is not an approved indication anywhere
LixisenatideBenefits, Dosage & Interactions
Also known as: Adlyxin
Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of medications used primarily in the management of type 2 diabetes mellitus. It is a synthetic analog of human GLP-1, a natural incretin hormone. Research on Lixisenatide focuses on blood sugar control and weight loss.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 3 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials and regulatory approval on file.
Plasma half-life
~3 h
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- GetGoal trials titrated from 10 mcg to a maintenance dose of 20 mcg once daily; the Parkinson's trial used 20 mcg once daily after titration[1][2][4]
Reported for Lixisenatide in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Lixisenatide entry is written from. Each number matches an inline marker above.
- [1]Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE · Diabetes Care · 2012 · Peer-reviewed · PMID 22432104
- [2]Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized TrialMeneilly GS, Roy-Duval C, Alawi H, et al. · Diabetes Care · 2017 · Peer-reviewed · PMID 28188240
- [3]Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trialsAhrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R · Diabetes, Obesity & Metabolism · 2014 · Peer-reviewed · PMID 24641271
- [4]Trial of Lixisenatide in Early Parkinson's DiseaseMeissner WG, Remy P, Giordana C, et al. · The New England Journal of Medicine · 2024 · Peer-reviewed · PMID 38598572
How to track Lixisenatide doses
Lixisenatide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Lixisenatide is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Lixisenatide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 3 h, effects and timing shifts show up over days rather than instantly. Review Lixisenatide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Lixisenatide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Lixisenatide studied for?
What is Lixisenatide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of medications used primarily in the management of type 2 diabetes mellitus. It is a synthetic analog of human GLP-1, a natural incretin hormone. GLP-1 is released from the intestines in response to food intake and plays a crucial role in glucose metabolism. Lixisenatide was approved by the U.S. Food and Drug Administration (FDA) in 2016 for the treatment of type 2 diabetes. It is administered via subcutaneous injection. Early research also explored its potential role in weight management due to its effects on appetite and gastric emptying (FDA label, DrugBank).
What does the research say about Lixisenatide?
Tap a section to expand.
Lixisenatide functions by selectively binding to and activating the GLP-1 receptor, which is expressed in pancreatic beta cells, alpha cells, and in the central nervous system. Activation of these receptors in the pancreas leads to several glucose-dependent effects. When blood glucose levels are elevated, lixisenatide stimulates insulin secretion from pancreatic beta cells. This effect is glucose-dependent, meaning it tends to diminish as blood glucose levels approach normal, thereby reducing the risk of hypoglycemia compared to some other antidiabetic agents. Concurrently, lixisenatide suppresses glucagon secretion from pancreatic alpha cells, which helps reduce hepatic glucose production. Another significant mechanism is the slowing of gastric emptying. This contributes to better postprandial glucose control by delaying the absorption of carbohydrates into the bloodstream. It may also promote a feeling of fullness, potentially contributing to reduced food intake. Preclinical and clinical studies have also indicated direct and indirect effects of GLP-1 receptor agonists on satiety centers in the brain, contributing to their observed impact on body weight (EMA SmPC, DrugBank).
Source for this section: Sources for How does Lixisenatide work?: Jumps to this entry in the sources and references list at the end of the page.
The primary clinical benefits of lixisenatide are observed in individuals with type 2 diabetes mellitus. Its main documented advantage is improved glycemic control, particularly in reducing post-meal blood glucose levels. Clinical trials have demonstrated that lixisenatide, when used as an adjunct to diet and exercise, effectively lowers hemoglobin A1c (HbA1c) in patients with type 2 diabetes. This occurs through its glucose-dependent effects on insulin secretion, glucagon suppression, and slowed gastric emptying (Cochrane Review, FDA label).
Beyond glucose control, some studies have shown that lixisenatide may contribute to modest weight loss. This effect is thought to be mediated by its impact on gastric emptying and central satiety mechanisms, leading to reduced caloric intake. In some clinical trials, patients experienced a reduction in body weight compared to placebo. However, the extent of weight loss can vary significantly among individuals (Examine.com, PubChem).
Cardiovascular safety trials for lixisenatide have demonstrated that it does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and a history of cardiovascular disease. This is an important consideration for antidiabetic medications, as cardiovascular disease is a common comorbidity (NIH ODS).
The efficacy and safety of lixisenatide have been evaluated in numerous clinical trials, collectively known as the GetGoal program. These studies involved thousands of patients with type 2 diabetes and assessed its use as monotherapy, as well as in combination with oral antidiabetic agents (e.g., metformin, sulfonylureas, pioglitazone) and basal insulin (FDA label, EMA SmPC).
For glycemic control, clinical trials consistently showed statistically significant reductions in HbA1c levels compared to placebo when lixisenatide was added to existing antidiabetic regimens. For instance, studies demonstrated HbA1c reductions ranging from approximately 0.5% to 0.9% from baseline, depending on the background therapy and patient population (Cochrane Review). Postprandial glucose levels were also significantly reduced. The GetGoal-S study, which investigated lixisenatide in combination with basal insulin, showed improved glycemic control with a reduced necessity for rescue insulin, without increasing the risk of hypoglycemia significantly compared to placebo.
Regarding weight, a meta-analysis of multiple trials indicated that lixisenatide treatment was associated with a modest but statistically significant reduction in body weight compared to placebo or other active comparators that do not typically induce weight loss. The weight reduction observed is generally in the range of 1 to 3 kg (Examine.com).
The ELIXA study, a prominent cardiovascular outcomes trial, evaluated the cardiovascular safety of lixisenatide in patients with type 2 diabetes and a recent acute coronary syndrome. The study concluded that lixisenatide did not increase the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) compared to placebo over a median follow-up of 25 months (NIH ODS).
Common side effects associated with lixisenatide are primarily gastrointestinal in nature. These can include nausea, vomiting, diarrhea, and indigestion. These gastrointestinal side effects are often more frequent at the beginning of treatment and may subside over time. Other reported side effects include headache and dizziness. As with other injectable medications, local injection site reactions such as redness, itching, or swelling can occur (FDA label, Mayo Clinic). Hypoglycemia (low blood sugar) is a potential side effect, particularly when lixisenatide is used in combination with sulfonylureas or insulin. The risk of hypoglycemia is lower when lixisenatide is used as monotherapy or with metformin alone because its glucose-lowering effects are glucose-dependent. Allergic reactions, though rare, can occur and may include rash, itching, or swelling. Severe allergic reactions such as anaphylaxis are possible and require immediate medical attention. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Lixisenatide carries several warnings that should be considered. It has been associated with a risk of pancreatitis, including acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting) and instructed to discontinue lixisenatide and seek medical attention if symptoms develop. There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which sometimes required hemodialysis. This risk may be increased in patients experiencing severe gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea) leading to dehydration. Patients should be monitored for changes in renal function, especially those with pre-existing renal impairment (FDA label, DrugBank). Severe hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If a hypersensitivity reaction is suspected, discontinue lixisenatide and do not restart. The safety and efficacy of lixisenatide in patients with severe gastrointestinal disease, such as severe gastroparesis, have not been studied and its use is generally not recommended in these populations due to its mechanism of slowing gastric emptying. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Lixisenatide is contraindicated in patients with a history of a serious hypersensitivity reaction to lixisenatide or to any of the excipients in the formulation. While GLP-1 receptor agonists as a class have a Boxed Warning regarding the risk of thyroid C-cell tumors (including medullary thyroid carcinoma, or MTC) based on animal studies, lixisenatide's FDA labeling states that it is not known whether lixisenatide causes thyroid C-cell tumors, including MTC, in humans. Therefore, it is generally advised against in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). However, this is a class-effect warning and specific studies for lixisenatide have not established a direct link in humans. Lixisenatide has not been studied in patients with type 1 diabetes mellitus and should not be used in these patients. It is also not indicated for the treatment of diabetic ketoacidosis. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Caution should be exercised when co-administering lixisenatide with medications that require rapid gastrointestinal absorption, as lixisenatide slows gastric emptying. This effect can potentially alter the absorption rates of orally administered drugs. Specifically, patients taking medications with a narrow therapeutic index or those requiring rapid absorption (e.g., antibiotics, oral contraceptives, acetaminophen) should be monitored. It is generally recommended to administer oral medications that require rapid onset of action at least one hour before lixisenatide injection. For oral contraceptives, it is advised to take them at least one hour before or at least 11 hours after lixisenatide injection to ensure adequate absorption (FDA label). When lixisenatide is initiated or dose escalated in patients receiving a sulfonylurea or insulin, the dose of the concomitant sulfonylurea or insulin may need to be reduced to minimize the risk of hypoglycemia. Patients should monitor blood glucose levels more frequently when combining these medications. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Lixisenatide is typically administered once daily, by subcutaneous injection, within one hour before the first meal of the day. Consistent timing before the same meal each day is generally recommended to maintain a stable drug concentration and optimize its effects on postprandial glucose. Individual needs vary — talk to a licensed clinician. The dosage is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Lixisenatide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Lixisenatide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
Frequently asked questions about Lixisenatide
Lixisenatide is primarily used to improve blood sugar control in adults with type 2 diabetes mellitus, alongside diet and exercise (FDA label).
Some individuals using lixisenatide have experienced modest weight loss as a side effect, believed to be due to its effects on slowing gastric emptying and promoting satiety (Examine.com).
Lixisenatide is administered as a subcutaneous injection once daily. It is not an oral medication (DrugBank).
The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea, particularly when treatment is initiated (Mayo Clinic).
Clinical trials, such as the ELIXA study, have shown that lixisenatide does not increase the risk of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease (NIH ODS).
Lixisenatide is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 3 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Lixisenatide with no sign-up.
Lixisenatide is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 3 hours, which is what drives how often it is redosed. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a supplement like Lixisenatide with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Lixisenatide: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 3 hours is why protocols often split Lixisenatide across the day rather than using a single dose. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Lixisenatide clears quickly (plasma half-life around 3 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Lixisenatide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Lixisenatide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Trial of Lixisenatide in Early Parkinson's Disease(opens PubMed in a new tab)N Engl J Med · 2024 · PMID 38598572 · https://pubmed.ncbi.nlm.nih.gov/38598572/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 90472060(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/90472060
Verify at
Publisher search links for Lixisenatide. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Lixisenatide?
Plain-text summary, safe to quote verbatim:
Lixisenatide is a GLP-1 (glucagon-like peptide-1) receptor agonist, a class of medications used primarily in the management of type 2 diabetes mellitus. It is a synthetic analog of human GLP-1, a natural incretin hormone. Research on Lixisenatide focuses on blood sugar control and weight loss.
Source: DoseRoutine — https://doseroutine.com/library/lixisenatide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Lixisenatide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/lixisenatide
What compounds are similar to Lixisenatide?
Others in the glp1 category or studied for the same goals.
Which goals is Lixisenatide used for?
Other compounds studied for the same benefits as Lixisenatide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.